[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"kidney-tumors\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:kidney-tumors":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,75],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":39,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":74},"100642988","registry-of-minimally-invasive-cancer-treatment-using-spectral-angio-ct-image-guidance-100642988",false,"NCT07636148","Registry of Minimally Invasive Cancer Treatment Using Spectral Angio-CT Image Guidance","Prospective Registry of Spectral Angio-CT-Guided Interventional Oncology Procedures in Routine Clinical Practice","PreciseOnco","Inclusion Criteria:\n\n* Age ≥ 18 years;\n* Undergoing a clinically indicated IO procedure with a percutaneous or transarterial approach for solid tumors;\n* Use of spectral angio-CT image guidance as part of standard care;\n* Written confirmed consent.\n\nExclusion Criteria:\n\n* Patients who are declared incapacitated;\n* Patients suffering from psychic disorders that make a comprehensive judgement impossible.","ALL","18 Years",{"count":20,"type":21},2000,"ESTIMATED","3 Years","OBSERVATIONAL","This study collects data from patients undergoing minimally invasive, image-guided cancer treatments at participating hospitals in the Netherlands and France. All treatments are performed as standard clinical care and include procedures such as tumor ablation and catheter-based treatments of cancer in the liver, kidney, lung, and bone.\n\nDuring these procedures, a spectral angio-CT system is used for image guidance. This advanced CT scanner automatically captures additional imaging information beyond what is used in routine clinical decision-making. The goal of this study is to investigate how this additional imaging information is associated with treatment outcomes, and how it can be used in the future to improve treatment planning, procedural guidance, and prediction of treatment results.\n\nNo experimental interventions are performed. Participation does not alter the treatment or follow-up patients receive. Data are collected from medical records and imaging systems and stored securely for analysis.",[26,27,28,29,30,31,32,33,34,35,36,37,38],"Liver Cancer (Primary and Metastatic)","Lung Cancer (Diagnosis)","Bone Cancer Metastatic","Bone Cancer Tumor","Kidney Tumors","Renal Cancer","Hepatocellular Carcinoma (HCC)","Renal Cell Carcinoma (Kidney Cancer)","Renal Cell Carcinoma (RCC)","Musculoskeletal Cancers","Musculoskeletal Tumors","Bone Tumors","Lung Tumors",[40,41,42,43,44,45,46,47,48,49,50,51,52,53,54,55,56,57,58,59,60,61],"Spectral CT","Dual-layer detector CT","Angio-CT","Image-guided therapy","Interventional oncology","Thermal ablation","Radiofrequency ablation","Microwave ablation","Cryoablation","Transarterial chemoembolization","Transarterial radioembolization","Transarterial embolization","Local tumor control","Tumor recurrence","Progression-free survival","Hepatocellular carcinoma","Liver metastases","Renal cell carcinoma","Lung tumors","Musculoskeletal tumors","Registry","Multicenter","NOT_YET_RECRUITING","2026-06-03",{"date":65,"type":66},"2026-06-09","ACTUAL",{"date":68,"type":21},"2026-07-01",{"date":70,"type":21},"2030-12-31",{"name":72,"class":73},"Mark C Burgmans, MD PhD","OTHER",3,{"id":76,"slug":77,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":4,"eligibilityCriteria":81,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":82,"targetDuration":4,"studyType":84,"phases":85,"briefSummary":87,"conditions":88,"keywords":93,"overallStatus":103,"whyStopped":4,"lastUpdateSubmitDate":104,"lastUpdatePostDateStruct":105,"startDateStruct":107,"completionDateStruct":109,"leadSponsor":111,"locationsCount":113},"100597781","kidney-protective-intervention-with-salt-substitute-after-kidney-tumor-surgery-100597781","NCT07062952","Kidney-protective Intervention With Salt Substitute After Kidney Tumor Surgery","Kidney-protective Intervention With Salt Substitute After Kidney Tumor Surgery: a Single-center Randomized Controlled Study(KISS Study)","Inclusion Criteria:\n\n* Participants must meet all of the following criteria:\n\n  1. Voluntary participation with signed informed consent from both the primary participant and all cohabiting family members, with commitment to study procedures and follow-up;\n  2. Age ≥18 years at enrollment (when signing informed consent), any gender;\n  3. Diagnosed kidney tumor patients who underwent radical nephrectomy or partial nephrectomy (no restrictions on surgical approach);\n  4. Preoperative eGFR \\>60 ml\u002Fmin\u002F1.73m² (calculated by CKD-EPI equation);\n  5. Serum potassium \\\u003C4.8 mmol\u002FL;\n  6. Predominantly home-based dietary habits (\\>90% meals prepared at home, assessed via self-report);\n  7. Normal contralateral renal function at screening;\n  8. Normal cardiopulmonary and hepatic function:\n\nExclusion Criteria:\n\n* Participants will be excluded if they meet any of the following:\n\n  1. Participant or cohabiting family members currently using potassium-sparing diuretics or potassium supplements, or prior use of salt substitutes;\n  2. Post-discharge eGFR \\\u003C45 ml\u002Fmin\u002F1.73m² without significant fluctuation;\n  3. Comorbid chronic kidney diseases (e.g., diabetic nephropathy, lupus nephritis);\n  4. Preoperative history of urinary tract obstruction;\n  5. Cohabiting family member(s) with CKD (eGFR \\\u003C45 ml\u002Fmin\u002F1.73m²);\n  6. Planned postoperative nephrotoxic medications (e.g., anti-neoplastic agents, immunotherapy);\n  7. Uncontrolled diabetes (HbA1c ≥12%);\n  8. Uncontrolled hypertension (seated SBP ≥180 mmHg or DBP ≥110 mmHg), symptomatic hypotension (SBP \\\u003C90 mmHg), or clinically evident hypovolemia;\n  9. Preoperative proteinuria (≥1+ on dipstick);\n  10. Severe cardiovascular disease (NYHA Class III-IV), gastrointestinal obstruction, or hyperkalemia history;\n  11. BMI \\\u003C18.5 kg\u002Fm² or \\>30 kg\u002Fm²;\n  12. Participation in another clinical trial ≤30 days before randomization or concurrently;\n  13. Communication barriers or anticipated non-adherence;\n  14. Structural\u002Ffunctional urological abnormalities (e.g., duplicated kidneys, polycystic kidneys, renal artery stenosis, stones, BPH) or indwelling catheters;\n  15. Prior radiotherapy\u002Fablation\u002Fsurgery on the contralateral kidney;\n  16. Life expectancy \\\u003C6 months (e.g., metastatic renal carcinoma).",{"count":83,"type":21},200,"INTERVENTIONAL",[86],"NA","This clinical trial is an open-label, randomized controlled study designed to evaluate the efficacyand safety of salt substitutes in protecting renal function after kidney tumor surgery, aiming toprovide dietary renal protection strategies for postoperative kidney tumor patients. lt will alsoassess the feasibility of salt substitute intervention. The primary research questions are:\n\n1. Does a salt substitute diet significantly improve estimated glomerular filtration rate (eGFR) compared to a regular salt diet in postoperative kidney tumor patients?\n2. What is the safety profile of salt substitute intervention in postoperative kidney tumor patients?\n3. What is the compliance rate among postoperative kidney tumor patients using saltsubstitutes?\n4. ls the salt substitute intervention feasible?\n\nResearchers will compare the intervention group (salt substitute diet) with the control group (regular salt diet) to determine whether salt substitutes effectively improve postoperative eGFR in kidney tumor patients.\n\nParticipants will be required to:\n\n1. Consume salt substitutes or regular salt daily while strictly adhering to WHO-recommendedsalt intake levels for 1 year.\n2. Undergo scheduled baseline assessments at 1, 3, 6, and 12 months post-surgery, with 24-hoururine tests at months 1 and 6 to evaluate compliance.\n3. Receive regular monitoring of blood electrolytes, eGFR, and other renal function indicators.\n4. Document any adverse events or health status changes during the study period.",[30,89,90,91,92],"CKD","Salt Substitute","Nephrectomy","eGFR",[94,89,95,96,92,97,98,99,100,101,102],"kidney tumor","Salt substitute","nephrectomy","kidney protection","kidney function","open-label","randomized controlled trial","Renal function compensation","CKD with clinical significance","RECRUITING","2025-12-07",{"date":106,"type":66},"2025-12-15",{"date":108,"type":66},"2025-04-24",{"date":110,"type":21},"2027-12-31",{"name":112,"class":73},"Jinling Hospital, China",1]